Ortataxel

N/A

Report date: 2024/01/16 10:53:27
NME

Base Information

Drug NameOrtataxel
Drug Alias NameOrtataxelum奥他赛奥他紫杉醇BAY-59IDN-5109 +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTubulin inhibitorsP-glycoprotein 1 inhibitors
TargetsTubulinP-glycoprotein 1
Therapy Area/IndicationsMetastatic breast cancerKidney NeoplasmsCarcinoma, Non-Small-Cell Lung +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesPoland +[12] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesIndena
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTheradexRoswell Park Cancer InstituteBayer AG +[4] 
Active IndicationsN/A
Inactive IndicationsMetastatic breast cancerKidney NeoplasmsCarcinoma, Non-Small-Cell Lung +[9] 

Other Information

ATC CodeN/A
Related LinksWikipedia